Mo1322 Effect of a Fermented Milk Product Containing Bifidobacterium lactis CNCM I-2494 in Patients With Irritable Bowel Syndrome (IBS): A Randomized, Double-Blinded, Placebo-Controlled Trial

2016 ◽  
Vol 150 (4) ◽  
pp. S697
Author(s):  
Boris Le Nevé ◽  
Rémi Brazeilles ◽  
Denis Guyonnet ◽  
Lena Ohman ◽  
Hans Törnblom ◽  
...  
PLoS ONE ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. e0214273 ◽  
Author(s):  
Boris Le Nevé ◽  
Muriel Derrien ◽  
Julien Tap ◽  
Rémi Brazeilles ◽  
Stéphanie Cools Portier ◽  
...  

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e018362 ◽  
Author(s):  
Joong Il Kim ◽  
Pumsoo Kim ◽  
Jin-Hyun Lee ◽  
Yoo-Jin Kim ◽  
Na-rae Yang ◽  
...  

IntroductionIrritable bowel syndrome (IBS), known as a functional and organic gastrointestinal disorder, is a collection of symptoms that occur together and generally include pain or discomfort in the abdomen and changes in bowel movement patterns. Due to the limitations of conventional treatments, alternative IBS treatments are used by many patients worldwide. Samryungbaekchulsan (SRS), a herbal formula, has long been used for alleviating diarrhoea-predominant IBS (D-IBS) in traditional Korean medicine. Otilonium bromide (OB) is an antimuscarinic compound used to relieve spasmodic pain in the gut, especially in IBS. Although herbal formulae and Western drugs are commonly coadministered for various diseases in Korea, few clinical studies have been conducted regarding the synergic effects of these treatments for any disease, including D-IBS.Methods and analysisThis trial is a randomised, double-blinded, placebo-controlled, double-dummy, four-arm, parallel study. After a 2-week preparation period, 80 patients with D-IBS will be randomly assigned to one of four treatment groups consisting of SRS (water extract granules, 5 g/pack, three times a day) with OB (tablet form, one capsule three times a day) or their placebos, with treatment lasting for 8 weeks. Post-treatment follow-up will be conducted 4 weeks after the end of treatment. The primary outcome is the finding obtained using the Subject’s Global Assessment of Relief method. The secondary outcomes are the severity of symptoms related to D-IBS, determined using a 10-point scale, and the change in symptoms.Ethics and disseminationThis trial has full ethical approval of the Ethics Committee of Catholic Kwandong University International St. Mary’s Hospital (IS15MISV0033) and the Korean Ministry of Food and Drug Safety (30769). The results of the study will be disseminated through a peer-reviewed journal and/or conference presentations.Trial protocol versionIS15MISV0033 version 4.0 (25 July 2016).Trial registration numberKCT0001621(approval date: 10 August 2015).


2007 ◽  
Vol 74 (3) ◽  
pp. 367-373 ◽  
Author(s):  
Ulla Sairanen ◽  
Laura Piirainen ◽  
Soile Gråsten ◽  
Tuomo Tompuri ◽  
Jaana Mättö ◽  
...  

We investigated the effects of a probiotic fermented milk and inulin on gastrointestinal function and microecology. The study was double-blinded and comprised 66 healthy adults (22 male, 44 female), mean age 40 years (range, 22–60 years). After a 12-d baseline period the subjects were randomized to consume, for 3 weeks, 3×200 ml daily of either (1) a fermented milk with probiotics (Bifidobacterium longumBB536,Bifidobacteriumspp. 420 andLactobacillus acidophilus145), (2) a fermented milk with the same probiotics plus 4 g inulin, or (3) a control fermented milk. During the last 7 d of the baseline and the intervention periods, the subjects kept a record of their defaecation frequency and gastrointestinal symptoms, and collected all their faeces. Intestinal transit time, stool weight and faecal enzyme activities were measured. Thirty-nine subjects were randomized to give faecal samples for analysis of pH and microbes, including lactobacilli, bifidobacteria, coliforms,Escherichia coli,BacteroidesandClostridium perfringens. Consumption of fermented milk with probiotics or with probiotics and inulin increased the faecal number of lactobacilli (P=0·009,P=0·003) and bifidobacteria (P=0·046,P=0·038) compared with the baseline. Compared with the control fermented milk, both active products increased lactobacilli (P=0·005, ANCOVA). Subjects consuming fermented milk with probiotics and inulin suffered from gastrointestinal symptoms, especially flatulence, more than the others (P<0·001). In conclusion, the probiotic fermented milk product had a positive effect by increasing the number of lactobacilli and bifidobacteria in the colon. Inulin did not alter this effect but it increased gastrointestinal symptoms.


2016 ◽  
Vol 14 (4) ◽  
pp. 343 ◽  
Author(s):  
Vinay G Zanwar ◽  
Sunil V Pawar ◽  
Pravir A Gambhire ◽  
Samit S Jain ◽  
Ravindra G Surude ◽  
...  

2005 ◽  
Vol 68 (6) ◽  
pp. 1246-1252 ◽  
Author(s):  
CRISTINA MARTÍNEZ-VILLALUENGA ◽  
JUANA FRÍAS ◽  
CONCEPCIÓN VIDAL-VALVERDE ◽  
ROSARIO GÓMEZ

The raffinose family of oligosaccharides (RFOs) isolated from lupin seeds (Lupinus albus var. Multolupa) was evaluated for bifidogenic effects during the manufacture of probiotic fermented milk. A mixed starter inoculum was composed of Bifidobacterium lactis Bb-12 and Lactobacillus acidophilus (1:1). Lupins are a rich source of RFOs that can be used as functional food ingredients. The addition of RFOs to milk increased B. lactis Bb-12 and L. acidophilus populations at the final fermentation time compared with controls. Final fermentation products are positively affected by addition of RFOs, and time of fermentation was reduced from 12 to 10 h. When RFOs were added to milk, they were preferentially used as a carbon source (57.7%) compared with lactose (23.7%) at the end of fermentation. These results suggest that the eventual choice of B. lactis Bb-12 and L. acidophilus in a mixed culture at a 1:1 ratio and addition of RFOs to produce a fermented milk product would have the advantages of rapid growth and acidification rate and would likely increase the probiotic effect of the final functional product.


Sign in / Sign up

Export Citation Format

Share Document